Skip to main content

Table 2 Usage of drugs in those with and without resistant hypertension

From: Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country

Name of drug

Number of patients (%)

p value*

 

All

Resistant

Non resistant

 
 

(n = 277)

(n = 53)

(n = 224)

 

Anti-hypertensives

    

  ACEI

151 (54.5%)

37 (69.8%)

114 (50.9%)

<0.05

  α-blockers

21 (7.6%)

14 (26.4%)

7 (3.1%)

<0.001

  ARB

94 (33.9%)

22 (41.5%)

72 (32.1%)

NS

  β-blockers

143 (51.6%)

38 (71.7%)

105 (46.9%)

<0.01

  CCBs

131 (47.3%)

29 (54.7%)

102 (45.5%)

NS

  Furosemide

59 (21.3%)

26 (49.1%)

33 (14.7%)

<0.001

  Spiranolactone

8 (2.9%)

6 (11.3%)

2 (0.9%)

<0.01

  Thiazide

34 (12.3%)

16 (30.2%)

18 (8.0%)

<0.001

Other drugs

    

  Anti platelets

201 (72.6%)

37 (69.8%)

174 (77.7%)

NS

  Lipid lowering drugs

152 (54.9%)

25 (47.1%)

127 (56.7%)

NS

  Nitrates

139 (50.2%)

26 (49.1%)

113 (50.4%)

NS

  1. ACEI Antgiotensin Converting Enzyme Inhibitors, ARB Angiotensin-II Receptor Blockers, CCB Calcium Channel Blockers, NS Not Significant; *, p values for ‘Resistant’ Vs. ‘Non-resistant’ groups.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us